Active Ingredient(s): Altretamine
FDA Approved: * December 26, 1990
Pharm Company: * MGI PHARMA INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Hexalen Overview

Altretamine (trade name Hexalen) is an antineoplastic agent. It was approved by the U.S. FDA in 1990. Contents 1 Uses 2 Mechanism 3 Side effects 4 Interactions 5 See also 6 References Uses It is indicated for use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with cisplatin and/or alkylating agent-based combination.[1] It is not considered a first-line treatment,[2] but i...

Read more Hexalen Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Altretamine

Recent Hexalen Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Capsule: 50mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Hexalen: (2 results)

Sorted by National Drug Code
  • 58063-001 Hexalen 50 mg Oral Capsule by mgi Pharma, Inc.
  • 62856-001 Hexalen 50 mg Oral Capsule by Eisai Inc.

Other drugs which contain Altretamine or a similar ingredient: (1 result)